GRFS

Grifols Share Price

17.49
0.15 (0.87%)
Upgrade to Real-Time
Afterhours (Closed)
17.49
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Grifols SA GRFS NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
0.15 0.87% 17.49 20:00:00
Open Price Low Price High Price Close Price Prev Close
17.42 17.245 17.57 17.49 17.34
Bid Price Ask Price Spread News
16.70 18.63 1.93 - -
Trades Volume VWAP Dollar Volume Avg Volume
2,705 284,901  17.43  4,965,573 644,259
Last Trade Time Type Quantity Stock Price Currency
16:00:07 formt 467  17.49 USD

Grifols Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 11.87B 678.54M 678.54M  6.48B  808.80M 1.09 16.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  0.21 4.15% - -

more financials information »

News Grifols

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

GRFS Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years0.000.000.000.0000.000.0%

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's bioscience business contributed 78% of sales in 2019. Grifols also has smaller segments including diagnostics, hospital supplies, and biosupplies. Diagnostics is now roughly 14% of revenue following the Novartis and Hologic deals.


Your Recent History
NASDAQ
GRFS
Grifols
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.